Welcome to our dedicated page for FTRP news (Ticker: FTRP), a resource for investors and traders seeking the latest updates and insights on FTRP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FTRP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FTRP's position in the market.
Field Trip Health Ltd. (TSX: FTRP; Nasdaq: FTRP) announced the results of its Annual General and Special Meeting of Shareholders on September 24, 2021. A total of 59.09% of common shares were represented at the meeting. Nine director nominees were elected, with Ronan Levy receiving 90.48% support. The shareholders also appointed Ernst & Young as auditors and approved an Amended and Restated Equity Compensation Plan. For further details, the management information circular is available on SEDAR.
Field Trip Health Ltd. (FTRP) announces its participation in multiple conferences in September 2021, including:
- H.C. Wainwright 23rd Annual Global Investment Conference (Sept 13-15): CEO Joseph Del Moral and CSO Dr. Nathan Bryson will engage in a Fireside Chat.
- Oppenheimer Fall Healthcare Summit (Sept 21-23): Presentation by the management team on Sept 21 at 2:55 PM ET.
- Maxim Group Mental Health Conference (Sept 22): Participation in panel discussions.
- Cantor Virtual Global Health Conference (Sept 27-30): Presentation on Sept 29 at 9:20 AM ET.
Field Trip Health Ltd. (TSX: FTRP; NASDAQ: FTRP) has announced that its psychedelic compound FT-104 targets Treatment Resistant Depression (TRD) and Postpartum Depression (PPD). The company is shaping its clinical strategy as it prepares for Phase I clinical trials in early 2022. With a significant patient population for both indications—100 million for TRD and 400,000 for PPD annually in the U.S.—FT-104 is set to provide potentially faster-acting relief than current therapies. Notably, Dr. Anita H. Clayton has joined the Scientific Advisory Board to aid in these developments.
Field Trip Health Ltd. (TSX: FTRP) launched the KAP Co-op program allowing independent therapists to provide ketamine-assisted psychotherapy (KAP) at their centers. The initiative includes training programs for therapists, enabling them to enhance their skills in psychedelic-assisted therapies. Co-op Therapists, upon approval, will access Field Trip’s medical resources for KAP treatment pricing starting at $400. The first training session is set for October 8, 2021, in Seattle at a cost of $1,200. This program aims to address the global mental health crisis through innovative therapy options.
Field Trip Health Ltd. (TSX: FTRP) reported significant progress in its fiscal first quarter 2022, with patient services revenue rising to $867,400, a 65% increase from the previous quarter. The company had approximately $100 million in unrestricted cash and equivalents as of June 30, 2021, and is on track to open 20 clinic sites by December 2021. The development of FT-104 continues, with GMP production achieved and Phase 1 human trials planned for Q1 2022. However, the company faced a net loss of $12.53 million due to high operating costs.
Field Trip Health Ltd. (TSX: FTRP, Nasdaq: FTRP) announced plans to release its financial results for the first fiscal quarter ended June 30, 2021, after market close on August 16, 2021. A conference call and webcast reviewing the results will take place on August 17, 2021, at 8:30 am ET. Investors can access the call via phone or through the company's Investor Relations website. Field Trip is recognized for its innovative work in psychedelic therapies and aims to enhance healing through evidence-based treatments.